Nipocalimab's Unique Mechanism Gets Second Chance in RA
The trial proved that nipocalimab reduced IgG antibodies, including anti-citrullinated protein autoantibodies, but the primary endpoint was missed.
Medscape Medical News
source https://www.medscape.com/viewarticle/nipocalimabs-unique-mechanism-gets-second-chance-rheumatoid-2024a100091h?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/nipocalimabs-unique-mechanism-gets-second-chance-rheumatoid-2024a100091h?src=rss
Comments
Post a Comment